VYNE - Biotech Catches Major Premarket Bid

A New Jersey-based %Biotech company is turning heads on Tuesday after the company announced the first %Vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201.

This press release caused shares of %VYNETherapeutics () to be bid up during Tuesday’s premarket as traders are currently willing to buy at $0.3057/share (+59.22% implied open for sellers) at the time of writing. This move will be a strong continuation of the success this micro cap has had so far this year.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD ( %AtopicDermatitis ). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include %AMZEEQ and %ZILXI .